Literature DB >> 31149104

A COMPARATIVE ANALYSIS OF THE INITIAL EAST EUROPEAN CENTER EXPERIENCE WITH A WESTERN HIGH-VOLUME CENTER FOR OPEN MINIMALLY INVASIVE PARATHYROIDECTOMY (OMIP) AS TREATMENT OF PRIMARY HYPERPARATHYROIDISM.

R M Neagoe1, D T Sala2, I Pascanu3, S Voidazan4, L Wang5, M Lansdown5, I T Cvasciuc5.   

Abstract

OBJECTIVE: To compare results of treatment of primary hyperparathyroidism (PHPT) in two teaching hospitals (eastern and western Europe) and to establish conclusions regarding quality of surgery for PHPT in Romania.
METHODS: We reviewed two prospectively collected databases of patients submitted to open minimally invasive parathyroidectomy (OMIP) for symptomatic PHPT in two centers from Romania and the United Kingdom (UK). We included patients with biochemically proven PHPT and positive pre-operative localization studies. We excluded patients with negative localization studies, suspected multiglandular disease, concomitant thyroid disorders and chronic renal failure.
RESULTS: 60 patients were included, 27 in group A (Romanian cohort) and 33 in group B (UK cohort). We noted significant differences between groups in pre-operative serum calcium and phosphorus levels (p<0.5). There were no differences between groups regarding the presence of symptoms; in group A we had significantly more patients with renal calculi history (p=0.02), digestive symptoms (p=0.006) and osteitis fibrosa cystica (p=0.01). Two patients from the UK group had lithium associated hyperparathyroidism and 2 patients had genetic disease. Intraoperative parathyroid hormone measurement (ioPTH) was available only for group B and frozen sections were selectively used in both groups. Both the adenoma size and weights were significantly higher in group A. The median operative time was significantly longer in Romanian group (p=0.001); in this group we noted the single conversion to traditional cervicotomy (3.7%) from all studied patients. In group A we noted two patients (7.4%) with failed parathyroidectomy and persistent PHPT; the cure rate was 92.5% for Romanian group and 97% for the UK group.
CONCLUSIONS: OMIP can be performed safe with a high cure rate in "small" volume endocrine centres with results comparable to western experienced endocrine centres. Romanian patients presented with more severe PHPT with more frequent end-organ damage, due probably to late diagnosis.

Entities:  

Keywords:  comparative analysis; minimally invasive; parathyroidectomy; primary hyperparathyroidism

Year:  2016        PMID: 31149104      PMCID: PMC6535260          DOI: 10.4183/aeb.2016.297

Source DB:  PubMed          Journal:  Acta Endocrinol (Buchar)        ISSN: 1841-0987            Impact factor:   0.877


  22 in total

1.  Worldwide trends in the surgical treatment of primary hyperparathyroidism in the era of minimally invasive parathyroidectomy.

Authors:  Wendy R Sackett; Bruce Barraclough; Tom S Reeve; Leigh W Delbridge
Journal:  Arch Surg       Date:  2002-09

2.  Randomized clinical trial comparing scan-directed unilateral versus bilateral cervical exploration for primary hyperparathyroidism due to solitary adenoma.

Authors:  C F J Russell; S J Dolan; J D Laird
Journal:  Br J Surg       Date:  2006-04       Impact factor: 6.939

3.  Unilateral versus bilateral neck exploration for primary hyperparathyroidism: a prospective randomized controlled trial.

Authors:  Anders Bergenfelz; Pia Lindblom; Sten Tibblin; Johan Westerdahl
Journal:  Ann Surg       Date:  2002-11       Impact factor: 12.969

4.  The predictive value of laboratory findings in patients with primary hyperparathyroidism.

Authors:  Géza Mózes; Kathleen J Curlee; Charles M Rowland; Jon A van Heerden; Geoffrey B Thompson; Clive S Grant; David R Farley
Journal:  J Am Coll Surg       Date:  2002-02       Impact factor: 6.113

5.  Unusual presentation of a giant parathyroid adenoma: report of a case.

Authors:  Colm Power; Dara Kavanagh; Arnold D K Hill; Niall O'Higgins; Enda McDermott
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

Review 6.  A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003.

Authors:  James M Ruda; Christopher S Hollenbeak; Brendan C Stack
Journal:  Otolaryngol Head Neck Surg       Date:  2005-03       Impact factor: 3.497

7.  Conventional bilateral cervical exploration versus open minimally invasive parathyroidectomy under local anaesthesia for primary hyperparathyroidism.

Authors:  A Bergenfelz; V Kanngiesser; A Zielke; C Nies; M Rothmund
Journal:  Br J Surg       Date:  2005-02       Impact factor: 6.939

8.  Incision length for standard thyroidectomy and parathyroidectomy: when is it minimally invasive?

Authors:  Laurent Brunaud; Rasa Zarnegar; Nobuyuki Wada; Philip Ituarte; Orlo H Clark; Quan-Yang Duh
Journal:  Arch Surg       Date:  2003-10

9.  Negative preoperative localization studies are highly predictive of multiglandular disease in sporadic primary hyperparathyroidism.

Authors:  Frederic Sebag; Johnathan G H Hubbard; Sylvie Maweja; Claudia Misso; Laurent Tardivet; Jean-Francois Henry
Journal:  Surgery       Date:  2003-12       Impact factor: 3.982

10.  Minimally invasive video-assisted parathyroidectomy versus open minimally invasive parathyroidectomy for a solitary parathyroid adenoma: a prospective, randomized, blinded trial.

Authors:  Marcin Barczyński; Stanisław Cichoń; Aleksander Konturek; Wojciech Cichoń
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

View more
  2 in total

1.  The effect of implementing pre-surgical ultrasound-guided fine-needle aspiration biopsy on thyroid surgery, a 6-year interrupted time series analysis in Qilu Hospital of Shandong University.

Authors:  Zhiyan Liu; Shaofeng Sui; Peng Su; Xiaofang Zhang; Jing Hu; Feifei Sun; Bo Han
Journal:  Gland Surg       Date:  2020-10

2.  ARE THYROID NODULES AN OBSTACLE TO MINIMAL INVASIVE PARATHYROID SURGERY? A SINGLE-CENTER STUDY FROM AN ENDEMIC GOITER REGION.

Authors:  S Özden; B Saylam; G Daglar; Y N Yuksek; M Tez
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Oct-Dec       Impact factor: 0.877

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.